E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Fractures of the tibial plateau requiring grafting |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10024956 |
E.1.2 | Term | Lower limb fractures |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the effects of a single implant of I-0401 (2 different concentrations) given in addition to internal fixation in tibia plateau fractures requiring grafting. |
|
E.2.2 | Secondary objectives of the trial |
- To assess the tolerability and safety of I-0401. - To assess pharmacokinetics of PTH.· - To assess quality of life and pharmacoeconomics. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Radiological evidence of fracture of the tibial plateau requiring grafting and fixation that occurs either alone or is part of a polytraumatic event (AO classification: 41B2, 41B3, 41C2, 41C3). 2. Female and male subjects ≥ 18 years. 3. Body mass index (BMI) 16-33 (minimum body weight 50 kg, maximum 140 kg). 4. Glasgow coma score (GCS) ≥ 13. 5. Females of child-bearing potential must be willing to undergo a pregnancy test (urine) prior to treatment start (at screening). 6. Females of child-bearing potential randomized in the intervention group must agree to have acceptable contraception for at least 3 months after receiving I 0401. 7. Subjects must be able and willing to come to the clinic for follow up visits as scheduled in the time and events schedule. 8. Signed Informed Consent Form (ICF).
|
|
E.4 | Principal exclusion criteria |
1. Total size of defect requiring a graft volume of > 7.0 mL. 2. Patients with high risk of amputation. 3. Open tibial plateau fractures Gustilo-Anderson grade III. 4. Concomitant ipsilateral fractures of the limb other than the fracture of the tibial plateau. 5. Active or past history of malignant tumor. 6. Evidence of systemic or localized infection at time of surgery. 7. Pregnant or lactating females. 8. Evidence of immune-suppression. 9. On treatment and/or planned treatment with products containing PTH (e.g. Forteo®, Forsteo®). 10. Evidence of hypercalcemia. 11. Known history of allergy to anesthetics. 12. Suspected or known allergies towards any of the components of I-0401 (TGplPTH1-34, Fibrin, HA/TCP granules). 13. History or evidence for any hereditary or acquired chronic bone disease. 14. Known clinically significant organ or systemic diseases or any other relevant medical condition such that in the opinion of the investigator, the significance of the disease or condition will impose hazard to the patient if study therapy will be initiated or will compromise the subject’s participation in the study. 15. Participation in another clinical trial within 3 months prior to trial start.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The proportion of patients with radiological fracture union at 16 weeks after implantation of the graft. Assessments will be performed by an independent radiological panel and will be based on CTs. Radiological fracture union will be defined using the following criteria: - Cortical bridging on at least 1 visible cortical plane and - Obliteration of fracture lines and - Dislocation of bone fragments compared to the post-operative film. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 14 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 3 |